$TPST ($TPST) is expected to release its quarterly earnings data on Wednesday, March 19th after market close, per Finnhub. Analysts are expecting revenue of $0 and ...

BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated ...

(RTTNews) - Tempest Therapeutics (TPST), a clinical-stage biotechnology company focused on cancer therapies, announced Thursday that it has received a "Study May Proceed" letter from the U.S. Food ...